The specter of generic challenges has consistently loomed around copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the future of related pharmaceutical portfolios. While early times saw impressive profits, the patent expiration has created the door for less expensive copies, likely lowering revenue and posing a real hazard for